MedTrace Logo

Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis

NCT02685033 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-01-04

Study results available
· View outcomes & findings →

Summary

This clinical study will be a single-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.

Conditions

  • Osteomyelitis

Interventions

DRUG

Dalbavancin

DRUG

Comparator

Sponsors & Collaborators

  • Durata Therapeutics Inc., an affiliate of Allergan plc

    lead INDUSTRY

Principal Investigators

  • Urania Rappo, MD, MS, PharmD · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-15
Primary Completion
2017-12-12
Completion
2017-12-12
FDA Drug
Yes

Countries

  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02685033 on ClinicalTrials.gov